JPH11512736A5 - - Google Patents

Info

Publication number
JPH11512736A5
JPH11512736A5 JP1997514119A JP51411997A JPH11512736A5 JP H11512736 A5 JPH11512736 A5 JP H11512736A5 JP 1997514119 A JP1997514119 A JP 1997514119A JP 51411997 A JP51411997 A JP 51411997A JP H11512736 A5 JPH11512736 A5 JP H11512736A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997514119A
Other languages
English (en)
Japanese (ja)
Other versions
JP4108750B2 (ja
JPH11512736A (ja
Filing date
Publication date
Priority claimed from IL11535795A external-priority patent/IL115357A/xx
Application filed filed Critical
Publication of JPH11512736A publication Critical patent/JPH11512736A/ja
Publication of JPH11512736A5 publication Critical patent/JPH11512736A5/ja
Application granted granted Critical
Publication of JP4108750B2 publication Critical patent/JP4108750B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP51411997A 1995-09-20 1996-09-18 Ｎ−プロパルギル−１−アミノインダンを含有する安定な組成物 Expired - Lifetime JP4108750B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL115357 1995-09-20
IL11535795A IL115357A (en) 1995-09-20 1995-09-20 Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
PCT/IL1996/000115 WO1997012583A2 (en) 1995-09-20 1996-09-18 Stable compositions containing n-propargyl-1-aminoindan

Publications (3)

Publication Number Publication Date
JPH11512736A JPH11512736A (ja) 1999-11-02
JPH11512736A5 true JPH11512736A5 (OSRAM) 2004-09-30
JP4108750B2 JP4108750B2 (ja) 2008-06-25

Family

ID=11068003

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51411997A Expired - Lifetime JP4108750B2 (ja) 1995-09-20 1996-09-18 Ｎ−プロパルギル−１−アミノインダンを含有する安定な組成物

Country Status (13)

Country Link
US (1) US6126968A (OSRAM)
EP (1) EP0858328B1 (OSRAM)
JP (1) JP4108750B2 (OSRAM)
AT (1) ATE362755T1 (OSRAM)
AU (1) AU728524B2 (OSRAM)
CA (1) CA2232310C (OSRAM)
DE (1) DE69637096T2 (OSRAM)
DK (1) DK0858328T3 (OSRAM)
ES (1) ES2287940T3 (OSRAM)
HU (1) HU225859B1 (OSRAM)
IL (1) IL115357A (OSRAM)
PT (1) PT858328E (OSRAM)
WO (1) WO1997012583A2 (OSRAM)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
CA2387394C (en) 1999-10-27 2009-08-18 Teva Pharmaceutical Industries, Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
PT1567152E (pt) * 2002-11-15 2013-10-03 Teva Pharma Uso de rasagilina com riluzol para tratar a esclerose lateral amiotrófica
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
CA2587295A1 (en) * 2004-11-10 2006-05-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
NZ555470A (en) * 2004-11-24 2011-02-25 Teva Pharma Rasagiline orally disintegrating compositions
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
ES2420404T3 (es) * 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
KR20170023211A (ko) * 2005-02-23 2017-03-02 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
CN101622225B (zh) 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
ES2632638T3 (es) 2005-12-09 2017-09-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigilo de baja dosis para el tratamiento de la deficiencia cognitiva
ES2551481T3 (es) 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
NZ571591A (en) 2006-04-03 2011-09-30 Teva Pharma Use of rasagiline for the treatment of restless legs syndrome
DE202006020710U1 (de) 2006-05-09 2009-12-31 Teva Pharmaceutical Industries Ltd. Zusammensetzungen mit Rosiglitazonmaleat
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
WO2008076315A1 (en) 2006-12-14 2008-06-26 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
HRP20110980T1 (hr) * 2006-12-14 2012-02-29 Teva Pharmaceutical Industries Ltd. Kristalna kruta rasagilinska baza
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
NZ586025A (en) * 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
EP2271612B1 (en) * 2008-03-31 2016-08-10 Actavis Group PTC EHF Rasagiline mesylate particles and process for the preparation thereof
CA2727022A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries Ltd. Rasagiline for parkinson's disease modification
JP2011524907A (ja) 2008-06-19 2011-09-08 テバ ファーマシューティカル インダストリーズ リミティド 固体ラサギリン塩基を調製および乾燥する方法
EP2299993A4 (en) * 2008-06-19 2014-08-20 Teva Pharma PROCESS FOR PURIFYING THE BASE OF RASAGILINE
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20120122993A1 (en) 2009-03-05 2012-05-17 Sandoz Ag Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-(1r)-, methanesulfonate
DK2451771T3 (da) 2009-07-09 2014-09-08 Ratiopharm Gmbh Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
WO2011087791A1 (en) 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
CA2793571C (en) 2010-04-30 2015-10-13 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
EP2389927A1 (en) 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of rasagiline
CA2806740A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
US8691872B2 (en) 2010-07-27 2014-04-08 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
WO2012129429A2 (en) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
JP2014534196A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン
EP2766007A4 (en) * 2011-10-10 2015-03-25 Teva Pharma RASAGILINE CITRAMIDE
EP2766004A4 (en) 2011-10-10 2015-04-22 Teva Pharma R (+) - N-methyl-propargyl-aminoindan
US9913812B2 (en) 2011-11-09 2018-03-13 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
DE102012000786A1 (de) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
EP2827848B1 (en) 2012-03-21 2016-04-27 Synthon BV Stabilized pharmaceutical compositions comprising rasagiline salts
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
BR112015003451A2 (pt) 2012-08-17 2017-07-04 Teva Pharma formulação parentérica de rasagilina
KR101856515B1 (ko) 2012-11-02 2018-05-10 테이코쿠 팔마 유에스에이, 인코포레이티드 프로피닐아미노인단 경피 조성물
ES2502140T1 (es) * 2013-02-06 2014-10-02 Galenicum Health S.L. Comprimidos de liberación inmediata de rasagilina hemitartrato
ES2524865T1 (es) * 2013-02-06 2014-12-15 Galenicum Health S.L. Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
CN115400090A (zh) * 2022-10-09 2022-11-29 北京新领先医药科技发展有限公司 一种雷沙吉兰的口崩片组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL112779A (en) * 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
WO1996026720A1 (en) * 1995-03-02 1996-09-06 R.P. Scherer Limited Pharmaceutical compositions comprising monoamine oxidase b inhibitors

Similar Documents

Publication Publication Date Title
JP2000500228A5 (OSRAM)
JP2000500445A5 (OSRAM)
JP2000500033A5 (OSRAM)
JP2000500440A5 (OSRAM)
JPH11508813A5 (OSRAM)
JP2000500327A5 (OSRAM)
JP2000500145A5 (OSRAM)
JP2000500155A5 (OSRAM)
JP2000500406A5 (OSRAM)
JP2000500361A5 (OSRAM)
JP2000500115A5 (OSRAM)
JP2000500322A5 (OSRAM)
JP2000500258A5 (OSRAM)
JP2000500342A5 (OSRAM)
JP2000500192A5 (OSRAM)
JP2000500112A5 (OSRAM)
JP2000500226A5 (OSRAM)
JP2000500051A5 (OSRAM)
JP2000500407A5 (OSRAM)
JP2000500397A5 (OSRAM)
JP2000500166A5 (OSRAM)
JP2000500125A5 (OSRAM)
JP2000500044A5 (OSRAM)
JP2000500346A5 (OSRAM)
JP2000500257A5 (OSRAM)